Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis

Molecular Carcinogenesis

Volumn 25, Issue 4, 1999, Pages 231-240

  Fischer, Susan M ^a   Lo, Herng Hsang ^a   Gordon, Gary B ^b   Seibert, Karen ^b   Kelloff, Gary ^c   Lubet, Ronald A ^c   Conti, Claudio J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b PFIZER INC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cyclooxygenase; Skin carcinogenesis; Ultraviolet light

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; EDEMA; INFLAMMATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SKIN CANCER; SKIN CARCINOGENESIS; ULTRAVIOLET RADIATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; CELL DIVISION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEEDING BEHAVIOR; INDOMETHACIN; ISOENZYMES; MICE; MICE, INBRED HRS; NEOPLASMS, RADIATION-INDUCED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SKIN NEOPLASMS; SULFONAMIDES; ULTRAVIOLET RAYS;

EID: 0032815072     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199908)25:4<231::AID-MC1>3.0.CO;2-F     Document Type: Article

References (41)

1. Ananthaswamy HN. Ultraviolet light as a carcinogen. In: Bowden GT, Fischer SM, editors. Comprehensive toxicology. New York: Elsevier; 1997. p 255-279.
2. Yuspa SH, Dlugosz AA. Cutaneous carcinogenesis: Natural and experimental. In Goldsmith LA, editor. Physiology, biochemistry and molecular biology of the skin. 2nd ed., Vol. II. New York: Oxford University Press; 1991. p 1365-1402.
3. Hruza LL, Pentland AP. Mechanisms of UV-induced inflammation. J Invest Dermatol 1993;100:35S-41S.
4. 2 in human skin. Am J Physiol 1996;39:C1037-C1050.
5. Morrison WL, Paul BS, Parrish JA. The effects of indomethacin on long-wave length ultraviolet-induced delayed erythema. J Invest Dermatol 1977;68:120-133.
6. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998;38:97-120.
7. Müller-Decker K, Scholz K, Marks F, Fürstenberger G. Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Mol Carcinog 1995;12:31-41.
8. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cycooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-6614.
9. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1993;44:1-10.
10. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-3232.
11. Wallace JL. Mechanism of non-steroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage - potential for development of gastrotintestinal tract safe NSAIDs. Can J Physiol Pharmacol 1994;72:1493-1498.
12. Khanna IK, Weier RM, Yu Y, et al. 1,2-diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents. J Med Chem 1997;40:11-15.
13. Fischer SM. Prostaglandins and cancer. Front Biosci 1997;2:d482-d500.
14. Fischer SM. Eicosanoids and tumor promotion. In: Muhktar H, editor. Skin cancer: Mechanisms and human relevance. Boca Raton, FL: CRC Press; 1995. p 129-144.
15. Berton TR, Mitchell DL, Fischer SM, Locniskar MF. Epidermal proliferation but not the quantity of DNA photodamage is correlated with UV-induced mouse skin carcinogenesis. J Invest Dermatol 1997;109:340-347.
16. Nakadate T, Yamamoto S, Aizu E, Kato R. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced increase in vascular permeability in mouse skin by lipoxygenase inhibitors. Jpn J Pharmacol 1985;38:161-168.
17. Balmain, A, Krumlauf R, Vass JK, Birnie GD. Cloning and characterization of the abundant cytoplasmic 7S RNA from mouse cells. Nucleic Acids Res 1982;10:203-207.
18. Leyton J, Lee ML, Locniskar M, et al. Effects of dietary fat on phorbol ester elicited tumor promotion and other events in mouse skin. Cancer Res 1991;51:907-915.
19. Fischer SM, Patrick KE, Patamali B, Slaga TJ. Effects of antihistamines on phorbol ester tumor promotion and vascular permeability changes. Carcinogenesis 1990;11: 991-996.
20. Thun MH, Namboordiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and reduced risk of fatal cancer. Cancer Res 1993;53:1322-1327.
21. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial polyposis. Cancer Res 1996;56:2556-2560.
22. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993;14:1493-1497.
23. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995;55:1464-1472.
24. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996;56:4566-4569.
25. Kawamori T, Rao CV, Seibert K, Reddy, BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58:409-411.
26. Rao CV, Tokumo K, Rogotty J, Zang E, Kelloff G, Reddy BS. Chemoprevention of colon carcinogenesis by dietary administration of piroxican, α-difluoromethylornithine, 16α-fluro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991;51:4528-4534.
27. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992;13:1019-1023.
28. Reeve VE, Matheson MJ, Bosnic M, Boehm-Wilcox C. The protective effect of indomethacin on photocarcinogenesis in hairless mice. Cancer Lett 1995;95:213-219.
29. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91: 12013-12017.
30. Fischer SM. Role of prostaglandins in tumor promotion. In: Slaga TJ, editor, Mechanisms of tumor promotion, Vol 2. Boca Raton, FL: CRC Press, Inc.; 1984. p 113-126.
31. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer. Carcinogenesis 1998;19: 723-729.
32. Kang-Rotondo CH, Miller CC, Morrison AR, Pentland AP. Enhanced keratinocyte prostaglandin synthesis after UV injury is due to increased phospholipase A2 activity. Am J Physiol 1993;264:C396-C401.
33. Fürstenberger G, Marks F. The role of eicosanoids in normal, hyperplastic and neoplastic growth in mouse skin. In: Ruzicka T, editor. Eicosanoids and the skin. Boca Raton, FL: CRC Press, Inc.; 1990. p 108-124.
34. Pentland AP, Needleman, PJ. Modulation of keratinocyte proliferation in vitro by endogenous prostaglandins. J Clin Invest 1986;77:246-251.
35. Tiano H, Chulada P, Spalding J, et al. Effects of cylcooxygenase deficiency on inflammation and papilloma development in mouse skin. Abstract. Proceedings of the American Association for Cancer Research 1997; 38:257.
36. Chulada P, Doyle C, Gaul B, et al. Cyclooxygenase-1 and -2 deficiency decrease spontaneous intestinal adenoma in Min mouse. Abstract. Proceedings of the American Association for Cancer Research 1998;39:195.
37. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809.
38. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Chin Invest 1997;99:2254-2259.
39. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995;109:994-998.
40. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin synthase-2. Cell 1995;83:493-501.
41. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998;95:681-688.